Welcome to our dedicated page for Mirum Pharmaceuticals SEC filings (Ticker: MIRM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Mirum Pharmaceuticals's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Mirum Pharmaceuticals's regulatory disclosures and financial reporting.
Mirum Pharmaceuticals grew Q1 2026 product sales to $159.9 million, up from $111.6 million a year earlier, driven by Livmarli and its bile acid medicines. Despite this growth, Mirum reported a net loss of $790.2 million, largely from a one-time $726.3 million acquired in-process R&D charge tied to its Bluejay Therapeutics acquisition and related stock-based compensation.
Mirum closed the Bluejay deal for brelovitug, a late-stage hepatitis D candidate, with total consideration of about $771.1 million, and raised $259.9 million through a private placement of common stock and pre-funded warrants. Unrestricted cash, cash equivalents and investments were $420.6 million as of March 31, 2026, and the company believes this will fund operations for at least twelve months while it advances late-stage programs in PSC, PBC, HDV and other rare diseases.
Mirum Pharmaceuticals reported first quarter 2026 net product sales of $159.9 million, up from $111.6 million a year earlier, and raised its 2026 net product sales guidance to $660–$680 million. Growth was driven by LIVMARLI sales of $113.8 million and bile acid medicines sales of $46.1 million.
Total operating expenses rose to $949.3 million, including $726.3 million of non-recurring in-process R&D from the Bluejay Therapeutics acquisition, resulting in a net loss of $790.2 million or $(13.43) per share. Mirum ended March 31, 2026 with $420.6 million in unrestricted cash, cash equivalents, and investments.
The company reported positive Phase 2b results for volixibat in primary sclerosing cholangitis and brelovitug in chronic hepatitis delta virus, with multiple Phase 3 readouts expected from H2 2026 through Q1 2027. Mirum also in-licensed worldwide rights to zilurgisertib for fibrodysplasia ossificans progressiva, paying $16 million upfront; the FDA granted Priority Review with a PDUFA date of September 26, 2026.
Mirum Pharmaceuticals reported that its VISTAS Phase 2b study of volixibat in primary sclerosing cholangitis met the primary endpoint for cholestatic itch relief. In the primary analysis cohort, volixibat 20 mg twice daily achieved a 2.72-point improvement on the Adult ItchRO scale versus 1.08 points for placebo, for a placebo-adjusted difference of 1.64 points (p<0.0001).
Statistically significant itch reductions appeared within two weeks and were also seen in patients with mild baseline itch. Safety was consistent with ileal bile acid transporter inhibition, with more gastrointestinal events and liver test elevations; diarrhea occurred in 40.3% of volixibat patients versus 8.6% on placebo, and more patients on volixibat discontinued treatment due to adverse events.
The company has a pre-New Drug Application meeting with the U.S. FDA for volixibat in PSC planned for summer 2026 and is targeting an NDA submission in the second half of 2026. Mirum also expects topline data from the VANTAGE Phase 2b volixibat study in primary biliary cholangitis in the first quarter of 2027.
BlackRock, Inc. reports beneficial ownership of 3,465,559 shares of Mirum Pharmaceuticals, Inc. common stock, representing 5.7% of the class. The filing shows sole voting power over 3,404,101 shares and sole dispositive power over 3,465,559 shares. The Schedule 13G/A is signed by a BlackRock Managing Director on 04/27/2026.
Mirum Pharmaceuticals reported positive Phase 2b results from the AZURE-1 study of brelovitug in chronic hepatitis delta virus (HDV). Among the first 53 patients evaluated at Week 24, virologic response was seen in 100% of patients on 300 mg weekly and 75% on 900 mg every four weeks, versus 0% in the delayed treatment arm.
The composite primary endpoint of virologic response plus ALT normalization was achieved by 45% and 35% of patients in the 300 mg and 900 mg arms, respectively, compared with 0% in the delayed arm. Treatment was generally well tolerated, with few grade 3 or higher and serious adverse events. Mirum plans to present full Phase 2b results at the EASL Congress in late May 2026 and expects topline data from Phase 3 AZURE-1 and AZURE-4 in H2 2026, with potential BLA submission and U.S. commercial launch in 2027.
Mirum Pharmaceuticals is asking stockholders to vote at its 2026 annual meeting on three key items: electing three Class I directors to serve until 2029, ratifying Ernst & Young LLP as auditor for 2026, and approving, on an advisory basis, executive compensation.
The meeting will be held in person on June 15, 2026 at 9:00 a.m. Pacific Time at Mirum’s Foster City, California headquarters. Stockholders of record as of April 20, 2026 can vote by internet, telephone, mail, or in person, with one vote per share. A quorum requires at least 30,488,921 of the 60,977,841 shares outstanding.
Mirum highlights a classified board structure with an independent Chair, describes committee independence and risk oversight, and notes robust stockholder engagement representing more than 70% of shares in 2025. The company reports 2025 net product sales of $521.3 million and emphasizes a pay-for-performance program, with 92.5% of CEO pay and 84.1% of other named executive officer pay at risk through bonuses and equity awards.
Mirum Pharmaceuticals director Saira Ramasastry exercised options and sold the resulting shares in a planned transaction. On April 15, 2026, she exercised a stock option to acquire 2,000 shares of Mirum common stock at $23.51 per share, from a fully vested option. The same day, she sold 2,000 common shares in an open-market transaction at $96.90 per share, leaving 0 shares of common stock reported as directly owned after the sale. The filing notes the activity occurred under a Rule 10b5-1 trading plan adopted on September 18, 2025, indicating the trades were pre-arranged.
MIRM filer submitted a Rule 144 notice reporting an intended sale of 2,000 shares of Common Stock on 04/15/2026 via a Stock Option Exercise for cash. The filing also lists two recent sales: 2,000 shares on 03/16/2026 for $181,520 and 2,000 shares on 02/13/2026 for $204,180.
Mirum Pharmaceuticals filed an amended report to add full financial details for its acquisition of Bluejay Therapeutics and a related equity financing. The filing includes Bluejay’s audited 2025 statements, showing $85.6 million in assets and a net loss of $101.7 million, highlighting its clinical-stage profile.
The amendment also provides unaudited pro forma results combining Mirum and Bluejay and reflecting Mirum’s $280.8 million upfront cash paid in the deal and a concurrent private placement of 3,385,149 shares and 536,412 pre-funded warrants, which generated approximately $268.5 million in gross proceeds.